Objectives: In our study, the role of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) in determining lymph node metastasis of endometrial cancer was evaluated.
INTRODUCTION
The most common gynecological neoplasm in industrialized countries is endometrial cancer [1] . The International Federation of Gynecology and Obstetrics (FIGO) recommends total hysterectomy with bilateral salpingo-oophorectomy and lymph node dissection for surgical staging of endometrial cancer [2, 3] . Prognosis in such patients is affected by numerous factors, such as tumor histology, grade, lymph node metastasis, depth of myometrial invasion, cervical invasion, lymphovascular invasion and patient's age [4, 5] . Pelvic lymph nodes are a common site of involvement in endometrial cancer, and patients with lymph node metastasis have considerably lower survival than patients without nodal metastasis [6, 7] . Randomized studies suggest that a routine systematic pelvic lymphadenectomy may contribute to surgical staging without any effect on survival in early-stage endometrial cancer [8, 9] . In this regard, the major role of lymphadenectomy is to decide on adjuvant therapy by contributing to the staging and the prediction of prognosis in endometrial cancer [10] . Lymph node dissection may cause significant morbidity, and metastasis may not be found in patients undergoing dissection [10] . Thus, the accurate prediction of lymph node status in preoperative period is important if futile lymph node dissection is to be avoided [11] . Magnetic resonance (MR) and computed tomography (CT) may fail to determine lymph node metastasis accurately [12, 13] . Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) is a commonly used method for the diagnosis and staging of numerous malignancies, and in evaluating response to therapy, providing both functional and anatomical information. It is suggested that functional changes that are detectable on a PET/CT precede morphological changes that can be detected using conventional CT and MR [14] .
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Objectıves
The authors of the present study assess the role of F-18 FDG PET/CT in determining lymph node metastasis of endometrial cancer.
MATERIAL AND METHODS

Patients
This retrospective study included 80 patients with a histopathological diagnosis of endometrial cancer who underwent preoperative F-18 FDG PET/CT in our department between February 2010 and March 2014.
Surgery
All patients underwent total hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy (external iliac, superficial and deep common iliac lymph nodes). There were positive lymph nodes in the pelvic and/or paraaortic areas on PET/CT scans in 7 patients. Furthermore, there were 43 patients with suspected for paraaortic lymph node metastasis during surgery. Therefore, these fifty patients underwent an additional paraaortic lymphadenectomies (precaval and paracaval, superficial and deep interaortocaval and paraaortic lymph nodes up to the renal vessels). All lymph nodes were evaluated by intraoperative inspection and palpation. Palpable, enlarged or fixed lymph nodes were regarded suspicious for malignancy. Furthermore, frozen section of uterine resection was evaluated in terms of tumor size, grade, histology and myometrial and cervical invasion status. Patients with myometrial invasion < 50% and without cervical invasion endometrioid cancer (grade 1 or tumor diameter < 2 cm grade 2) were considered to be at low risk for paraaortic lymph node metastasis, whereas others high risk. Paraaortic lymphadenectomy was performed in high-risk patients and those with suspicious lymph nodes during the operation.
There was a patient who was suspected to have omental metastasis during the operation, so she underwent omental resection. Although no metastasis was detected in frozen sections of the omentum, microscopic metastasis was found in the final histopathological evaluation. Since the distant metastasis of the patient with stage 4B could not be detected during the operation or preoperative PET/CT, lymphadenectomy was performed.
Histopathologic Evaluation of Lymph Nodes
Uterus, bilateral adnexal tissues, lymph nodes and any other resected tissues were analysed by experienced pathologists.
Lymph nodes were fixed with 10% formalin and then embedded in paraffin. Paraffin blocks were sliced and processed. Tissue sections were firstly stained with hematoxylin and eosin (H&E). If metastasis was detected in this proce-dure, no further histological examination was performed. If the serial H&E sections were negative, immunohistochemical (IHC) methods were performed. PAN-cytokeratin was used for IHC evaluation. Histopathologically, the lymph nodes were defined as benign and malignant.
F-18 FDG PET/CT
PHILIPS GEMINI TF 16 Slice PET/CT scan was used for imaging. Patients with a blood glucose level below 200 mg/dL following an at least 6 hours of fasting received an intravenous 8-11 mCi FDG injection. The urinary bladder was evacuated approximately 60 minutes after the injection, and the body area from the vertex of the skull to the upper femur was scanned. CT images were captured initially (140 kV, 100 mAs, 5 mm slice) followed by PET scans. PET scanning was performed at 9-10 bed positions depending on the height of the patient, each bed position lasting 90 seconds.
The blood pool activity was taken into consideration while evaluating the FDG uptake by the lymph nodes on PET/CT. Regardless of the lesion size, a lymph node showing a FDG uptake equal to or below the blood pool activity was considered negative for malignancy, and a FDG uptake above this threshold was considered positive for malignancy.
Data and Statistical Analyses
The histopathological examination results were considered as the reference standard in the evaluation of lymph node metastasis. A histopathological examination of the lymph nodes identified the lymph nodes as benign or malignant. The result of PET/CT was considered a true negative (TN) if it showed negative findings, and the result was considered false positive (FP) if the PET/CT showed positive findings in a histopathologically benign lymph node. The result of PET/CT was considered a true positive (TP) if it showed positive findings, and the result was considered a false negative (FN) if it showed negative findings in a histopathologically malignant lymph node. The accuracy, sensitivity and specificity of PET/CT in determining lymph node metastasis was calculated using a standard formula on a patient and lymph node basis. 
RESULTS
Patients and Histopathologic Findings
The study included 80 patients who had endometrial cancer with a mean age of 62 ± 5.4 years (range 37-80). All patients underwent a pelvic lymphadenectomy, while 50 patients underwent an additional paraaortic lymphadenectomy. Lymph node metastasis was detected in five patients, whereas 75 patients had no lymph node metastasis.
Of the patients with lymph node metastasis, one had endometroid and 4 had nonendometroid (mixed = 2, serous = 1, undifferentiated = 1) histology. The tumor grade was 2 in 1 patient and 3 in 4 patients. According to FIGO 2009 staging, 2 of the patients were in stage 3C1, 2 of them were in stage 3C2, 1 of them was in stage 4B.
In patients without lymph node metastasis the histologic types were endometrioid carcinoma (n = 47), adenocarcinoma with squamous differentiation (n = 10), squamous carcinoma (n = 8), undifferentiated carcinoma (n = 6), serous carcinoma (n = 2), clear cell carcinoma (n = 1) and mucinous carcinoma (n = 1). 22 cases were grade 1, 32 cases were grade 2 and 21 cases were grade 3. Of the 75 patients, 40 were stage 1A, 12 were stage 1B, 10 were stage 2, 5 were stage 3A and 8 were stage 3B.
When evaluated on an lymph node basis, of the total 1,471 lymph nodes, 1,046 were found in the pelvic area and 425 in the paraaortic area in a histopathological examination. Of these lymph nodes, 1,433 (pelvic lymph node = 1018, paraaortic lymph node = 415) were benign and 38 (pelvic lymph node = 28, paraaortic lymph node = 10) were malignant (Tab. 1).
Lymph Node Findings on PET/CT
Lymph node metastasis was detected in five out of 80 patients, whereas 75 patients had no lymph node metastasis. When evaluated on a patient basis, PET/CT was negative in 72 (TN) and positive (FP) in three of the 75 patients with a benign lymph node. PET/CT was positive in four (TP) and negative (FN) in one out of the five patients with at least one malignant lymph node on a histopathological examination. The results are presented in Table 2 . When evaluated on a patient basis, the accuracy, sensitivity and specificity of PET/CT in detecting lymph node metastasis was 95%, 80% and, 96% respectively.
When evaluated on an lymph node basis, PET/CT was positive in 20 (FP) and negative in 1,413 (TN) out of the 1,433 lymph nodes that qualified histopathologically as benign. PET/CT was positive in 30 (TP) and negative in eight (FN) of the 38 lymph nodes that qualified as malignant upon a histopathological examination. The results are presented in Table 3 . When evaluated on an lymph node basis, the accuracy, sensitivity and specificity of PET/CT in detecting lymph node metastasis was 97.4%, 78.9% and 98.6%, respectively. Sample lymph node findings of PET/CT that were evaluated based on histopathological results are presented in Figure 1 .
When 38 metastatic lymph nodes are grouped according to their short diameters; 3 of them were ≤ 4 mm, 27 were 5-9 mm, and 8 were ≥ 10 mm. PET/CT could not detect any metastatic lymph nodes with a short diameter of ≤ 4 mm, while it was true positive in 22 of those with a short diameter of 5-9 mm and in all of those with ≥ 10 mm. Thus, PET/CT was able to detect 22 of 30 metastatic lymph nodes with a short diameter of less than 10 mm (73.3%). The detection sensitivity of PET/CT was 0% (0/3), 81.4% (22/27) and 100% in metastatic lymph nodes with a short diameter of ≤ 4 mm, 5-9 mm and ≥ 10 mm, respectively.
DISCUSSION
Detecting the presence of lymph node metastasis in endometrial cancer is important in treatment decisions, as well as in predicting prognosis. However, only 20-25% of high-risk patients show nodal metastasis and up to 80% of patients undergo a futile systematic lymphadenectomy [15] . Furthermore, it has been demonstrated that a routine systematic lymphadenectomy offers no survival benefit in early-stage endometrial cancer [8, 9] . Lymph node dissection is currently considered the optimum method in determining the status of lymph nodes in endometrial cancer [11] , although there are ongoing efforts to identify a preoperative, predictive non-invasive method. Determining the status of lymph nodes preoperatively avoids futile lymph node dissection, thereby decreasing morbidity and reducing costs. CT and MR are commonly used methods in Results are shown as number the preoperative evaluation of patients with endometrial cancer. However, these conventional methods are predicated on the size of the lymph nodes in the evaluation and a short diameter of ≥ 10 mm is the most accepted criterion for the identification of suspected lymph nodes. On this point, it is inevitable that < 10 mm short diameter metastatic lymph nodes are underestimated by CT or MR. However, FDG PET/CT provides functional data while also identifying morphological changes, suggesting that it may be superior to anatomical visualization alone in the evaluation of the status of lymph nodes [14] . In the present study, there were 30 metastatic lymph nodes with < 10 mm short diameter. PET/CT was able to detect 22 of them (73.3%) and so had a great value in the detection of subcentimeter metastatic lymph nodes which have been disregarded by CT and MR. CT and MR are asserted to have a sensitivity of 29-66% and a specificity of 73-99% in various studies [12, 16, 17] .
A study involving 287 patients with endometrial cancer found that PET/CT was more sensitive than MR in detecting lymph node metastasis in a patient-based evaluation (70% vs. 34%), although specificity rates were similar (95.4% vs. 95%). The sensitivity and specificity of PET/CT were found to be 79.4% and 96.7% in an lymph node-based evaluation, with MR showing rates of 51.6% and 97.6%, respectively [18] . In a meta-analysis of 13 patient-based studies involving a total of 861 patients with endometrial cancer, the A total of 28 lymph nodes were dissected from the pelvic (n: 21) and paraaortic (n: 7) regions in the case, in which metastasis was suspected intraoperatively. Metastasis was determined in the five lymph nodes in the right external and internal iliac regions, while other lymph nodes were determined to be benign. The PET/CT was false negative in those five lymph nodes and true negative in the other 23 lymph nodes; C. An increased FDG uptake was noted in one lymph node in the paraaortic region and in three lymph nodes in the pelvic region in a PET/CT of a 49-year-old patient. Metastasis was determined positive in the four lymph nodes histopathologically, and hence PET/CT findings were evaluated to be true positive; D. An increased FDG uptake was noted in three lymph nodes in the paraaortic region and in three lymph nodes in the pelvic region on a PET/CT. No metastasis was determined to be positive histopathologically in the total number of 30 lymph nodes (22 pelvic, 8 paraaortic) in this case. The PET/CT findings were considered false positive in six lymph nodes and true negative in the remaining 24 lymph nodes pooled specificity of FDG PET/CT in detecting lymph node metastasis was 94% (93-96%) and the pooled sensitivity was 72% (63-80%) [14] . In another meta analysis of seven studies (243 patients with endometrial cancer), the pooled specificity and sensitivity of PET or PET/CT in detecting lymph node metastasis was 94.7% (90.4-97.4%) and 63% (48.7-75.7%), respectively [19] . In a study by Crivellaro et al. [15] [20] . In a study by Kitajima et al. [21] involving patients with endometrial cancer and cervical cancer and using a similar lymph node classification, sensitivity was 12.5%, 66.7% and 100%, respectively. Another study using FDG-PET detected no lymph node metastasis smaller than 6 mm [22] . The accuracy, sensitivity and specificity of PET/CT in detecting lymph node metastasis in the present study were found to be 95%, 80% and 96% in a patient-based evaluation, and 97.4%, 78.9% and 98.6% in an lymph node-based evaluation. Also, the detection sensitivity of PET/CT was 0%, 81.4% and 100% in metastatic lymph nodes with a short diameter of ≤ 4 mm, 5-9 mm and ≥ 10 mm, respectively. PET/CT could not detect any three metastatic nodes 4 mm or smaller. This is probably because of the currently used PET/CT techniques cannot detect micrometastatic diseases due to their low spatial resolution. The specificity of PET/CT in the present study was similar to literatüre results and, the sensitivity was higher than some of those reported in literature. The authors consider that lymph nodes evaluated in studies with variable sizes and the inability to recognize small-size lymph node metastasiss may result in different sensitivity rates being reported in such studies. For example, in our study, the rate of metastatic lymph nodes with a short diameter of ≤ 4 mm was 3/38 whereas in the study by Kitajima it was 16/45. Furthermore, the selection of low-or high-risk patients in some studies may have also affected the results.
CONCLUCIONS
The present study is limited by its retrospective design and the relatively small number of patients with lymph node metastasis. That said, PET/CT showed high sensitivity, specificity and accuracy in the detection of lymph node metastasis, and had a great value in the detection of subcentimeter ones. Therefore, PET/CT can direct the surgical procedure even though it does not completely replace the surgical staging.
